Kristen M Ward1, Larisa Yeoman2, Cora McHugh2, A Zarina Kraal3, Stephanie A Flowers4, Amy E Rothberg5, Alla Karnovsky6,7, Arun K Das5,7, Vicki L Ellingrod1,8, Kathleen A Stringer1,2,9. 1. Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan. 2. NMR Metabolomics Laboratory, College of Pharmacy, University of Michigan, Ann Arbor, Michigan. 3. Psychology Department, College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, Michigan. 4. Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago, Illinois. 5. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan. 6. Department of Bioinformatics and Computational Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan. 7. The Michigan Regional Comprehensive Metabolomics Resource Core, University of Michigan, Ann Arbor, Michigan. 8. Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan. 9. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
STUDY OBJECTIVE: Patients with schizophrenia are known to have higher rates of metabolic disease than the general population. Contributing factors likely include lifestyle and atypical antipsychotic (AAP) use, but the underlying mechanisms are unknown. The objective of this study was to identify metabolomic variability in adult patients with schizophrenia who were taking AAPs and grouped by fasting insulin concentration, our surrogate marker for metabolic risk. DESIGN: Metabolomics analysis PARTICIPANTS: Ninety-four adult patients with schizophrenia who were taking an AAP for at least 6 months, with no changes in their antipsychotic regimen for the previous 8 weeks, and who did not require treatment with insulin, participated in the study. Twenty age- and sex-matched nonobese (10 subjects) and obese (10 subjects) controls without cardiovascular disease or mental health diagnoses were used to match the body mass index (BMI) range of the patients with schizophrenia to account for metabolite concentration differences attributable to BMI. MEASUREMENTS AND MAIN RESULTS: Existing serum samples were used to identify aqueous metabolites (to differentiate fasting insulin concentration quartiles) and fatty acids with quantitative nuclear magnetic resonance and gas chromatography methods, respectively. To exclude metabolites from our pathway mapping analysis that were due to variability in weight, we also subjected serum samples from the nonobese and obese controls to the same analyses. Patients with schizophrenia had a median age of 47.0 years (interquartile range 41.0-52.0 years). Using a false discovery rate threshold of less than 25%, 10 metabolites, not attributable to weight, differentiated insulin concentration quartiles in patients with schizophrenia and identified variability in one-carbon metabolism between groups. Patients with higher fasting insulin concentrations (quartiles 3 and 4) also trended toward higher levels of saturated fatty acids compared with patients with lower fasting insulin concentrations (quartiles 1 and 2). CONCLUSION: Our results illustrate the utility of metabolomics to identify pathways underlying variable fasting insulin concentration in patients with schizophrenia. Importantly, no significant difference in AAP exposure was observed among groups, suggesting that current antipsychotic use may not be a primary factor that differentiates middle-aged adult patients with schizophrenia by fasting insulin concentration.
STUDY OBJECTIVE:Patients with schizophrenia are known to have higher rates of metabolic disease than the general population. Contributing factors likely include lifestyle and atypical antipsychotic (AAP) use, but the underlying mechanisms are unknown. The objective of this study was to identify metabolomic variability in adult patients with schizophrenia who were taking AAPs and grouped by fasting insulin concentration, our surrogate marker for metabolic risk. DESIGN: Metabolomics analysis PARTICIPANTS: Ninety-four adult patients with schizophrenia who were taking an AAP for at least 6 months, with no changes in their antipsychotic regimen for the previous 8 weeks, and who did not require treatment with insulin, participated in the study. Twenty age- and sex-matched nonobese (10 subjects) and obese (10 subjects) controls without cardiovascular disease or mental health diagnoses were used to match the body mass index (BMI) range of the patients with schizophrenia to account for metabolite concentration differences attributable to BMI. MEASUREMENTS AND MAIN RESULTS: Existing serum samples were used to identify aqueous metabolites (to differentiate fasting insulin concentration quartiles) and fatty acids with quantitative nuclear magnetic resonance and gas chromatography methods, respectively. To exclude metabolites from our pathway mapping analysis that were due to variability in weight, we also subjected serum samples from the nonobese and obese controls to the same analyses. Patients with schizophrenia had a median age of 47.0 years (interquartile range 41.0-52.0 years). Using a false discovery rate threshold of less than 25%, 10 metabolites, not attributable to weight, differentiated insulin concentration quartiles in patients with schizophrenia and identified variability in one-carbon metabolism between groups. Patients with higher fasting insulin concentrations (quartiles 3 and 4) also trended toward higher levels of saturated fatty acids compared with patients with lower fasting insulin concentrations (quartiles 1 and 2). CONCLUSION: Our results illustrate the utility of metabolomics to identify pathways underlying variable fasting insulin concentration in patients with schizophrenia. Importantly, no significant difference in AAP exposure was observed among groups, suggesting that current antipsychotic use may not be a primary factor that differentiates middle-aged adult patients with schizophrenia by fasting insulin concentration.
Authors: Marc De Hert; Weiping Yu; Johan Detraux; Kim Sweers; Ruud van Winkel; Christoph U Correll Journal: CNS Drugs Date: 2012-09-01 Impact factor: 5.749
Authors: Vicki L Ellingrod; Del D Miller; Stephan F Taylor; Jessica Moline; Timothy Holman; Jane Kerr Journal: Schizophr Res Date: 2007-10-31 Impact factor: 4.939
Authors: Robert A van den Berg; Huub C J Hoefsloot; Johan A Westerhuis; Age K Smilde; Mariët J van der Werf Journal: BMC Genomics Date: 2006-06-08 Impact factor: 3.969
Authors: T Suvitaival; O Mantere; T Kieseppä; I Mattila; P Pöhö; T Hyötyläinen; J Suvisaari; M Orešič Journal: Transl Psychiatry Date: 2016-11-15 Impact factor: 6.222
Authors: Kristen M Ward; Kyle Burghardt; A Zarina Kraal; Andrew Jaeger; Larisa Yeomans; Cora McHugh; Alla Karnovsky; Kathleen A Stringer; Vicki L Ellingrod Journal: Front Psychiatry Date: 2021-05-25 Impact factor: 4.157